BE888073A - DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES. - Google Patents
DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES.Info
- Publication number
- BE888073A BE888073A BE1/10185A BE1010185A BE888073A BE 888073 A BE888073 A BE 888073A BE 1/10185 A BE1/10185 A BE 1/10185A BE 1010185 A BE1010185 A BE 1010185A BE 888073 A BE888073 A BE 888073A
- Authority
- BE
- Belgium
- Prior art keywords
- imidazo
- preparation
- pyridine derivatives
- cardiotonic agents
- cardiotonic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/132,907 US4294836A (en) | 1980-03-24 | 1980-03-24 | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
Publications (1)
Publication Number | Publication Date |
---|---|
BE888073A true BE888073A (fr) | 1981-09-23 |
Family
ID=22456117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE1/10185A BE888073A (fr) | 1980-03-24 | 1981-03-23 | DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES. |
Country Status (5)
Country | Link |
---|---|
US (1) | US4294836A (fr) |
JP (1) | JPS56150089A (fr) |
KR (1) | KR830005216A (fr) |
BE (1) | BE888073A (fr) |
ZA (1) | ZA811903B (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5881033U (ja) * | 1981-11-28 | 1983-06-01 | 日本軽金属株式会社 | プレス型用クランプ装置 |
WO2008030408A2 (fr) * | 2006-09-05 | 2008-03-13 | Yale University | Composés protéomimétiques inhibant l'interaction d'un récepteur nucléaire avec des peptides de coactivateur |
EP2078016B1 (fr) * | 2006-10-19 | 2012-02-01 | Signal Pharmaceuticals LLC | Composés hétéroaryle, compositions de ceux-ci et procédés de traitement avec ceux-ci |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
NZ599549A (en) | 2009-10-26 | 2013-11-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
WO2013059396A2 (fr) | 2011-10-19 | 2013-04-25 | Signal Pharmaceuticals, Llc | Traitement du cancer avec des inhibiteurs de la kinase tor |
CN104093398B (zh) | 2011-12-02 | 2017-03-15 | 西格诺药品有限公司 | 7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法 |
BR112014020786A2 (pt) | 2012-02-24 | 2020-10-27 | Signal Pharmaceuticals, Llc | método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
EP2945636B1 (fr) | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux |
MX2015014589A (es) | 2013-04-17 | 2016-04-25 | Signal Pharm Llc | Tratamiento de cancer con dihidropirazino-pirazinas. |
EA029072B1 (ru) | 2013-04-17 | 2018-02-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты |
BR112015026021A2 (pt) | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法 |
WO2014172426A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Traitement du cancer par des dihydropyrazino-pyrazines |
WO2014172432A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Polythérapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer |
JP6382949B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法 |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
WO2016010886A1 (fr) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Méthodes de traitement d'un cancer à l'aide de composés de pyrrolopyrimidine substitués, compositions de ceux-ci |
IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838156A (en) * | 1973-03-29 | 1974-09-24 | Sterling Drug Inc | Certain 2-substituted-6-(3 or 4-pyridyl)-nicotinic acid derivatives |
US4072746A (en) * | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
US4152434A (en) * | 1976-04-22 | 1979-05-01 | Hexachimie | Morpholine containing imidzo[4,5-b]pyridines and use thereof |
IT1156732B (it) * | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
-
1980
- 1980-03-24 US US06/132,907 patent/US4294836A/en not_active Expired - Lifetime
-
1981
- 1981-03-23 ZA ZA00811903A patent/ZA811903B/xx unknown
- 1981-03-23 BE BE1/10185A patent/BE888073A/fr unknown
- 1981-03-23 KR KR1019810000983A patent/KR830005216A/ko unknown
- 1981-03-24 JP JP4307181A patent/JPS56150089A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR830005216A (ko) | 1983-08-03 |
ZA811903B (en) | 1982-04-28 |
JPS56150089A (en) | 1981-11-20 |
US4294836A (en) | 1981-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE888073A (fr) | DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES. | |
OA07130A (fr) | Nouvelles imidazo[1,2-a]pyridines et pyridazines . | |
DE3168433D1 (de) | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidin-4-one derivatives | |
PH20810A (en) | Imidazo(4,5-b)and(4,5-c)pyridine derivatives having cardiotonic activity | |
IL64220A0 (en) | Nicotinamide derivatives,their preparation and their use as herbicides | |
BE888122A (fr) | Diamino-pyridines, leur preparation et leur utilisation comme intermediaires et agents cardiotoniques | |
BE888088A (fr) | Imidazopyridines, leur preparation et leur utilisation comme agents cardiotoniques | |
ATE33651T1 (de) | Imidazo(1,5-a)pyridin-derivate. | |
ATE50259T1 (de) | 1,6-naphthyridin-2(1h)-one brauchbar als kardiotonika. | |
BE887890A (fr) | Derives de pyrazpolopyridine, leur preparation et leur utilisation comme agents cardiotoniques. | |
IL59538A0 (en) | 3-substituted pyridine derivatives,their preparation and their use as funigicides | |
IT8021821A0 (it) | Pirido [1,2-a] pirimidine sostituite | |
FI821035A0 (fi) | Imidazo/1,2-a/pyrimidinderivat, deras framstaellning och anvaendning vid sjukvaord | |
FR2542742B1 (fr) | Nouveaux derives de cyano-2 imidazo (4,5-b) pyridine. leur preparation et leur utilisation comme fongicides | |
BE891493A (fr) | Derives de 1,2-dihydro-5(pyridinyl) nicotinamide, leur preparation et leur utilisation comme agents cardiotoniques et intermediaires | |
DE3267918D1 (de) | Pyrazolo(3,4-b)pyridine derivatives | |
MA21032A1 (fr) | Derives d'imidazole , leur preparation et leur utilisation comme fongicides . | |
FI813757L (fi) | Nytt foerfarande foer framstaellning av imidazo/4,5-b/pyridiner och -pyrimidiner | |
DK33684D0 (da) | Pyrazino (2',3'-3,4)pyrido(1,2-a)-indol-derivater | |
BE887471A (fr) | Derives benzylideniques, leur preparation et leur utilisation | |
FR2536407B1 (fr) | Nouveaux derives de la pyridone, leur preparation et leur utilisation comme colorants | |
BE879732A (fr) | Derives d'acyl-1h-1,2,4-triazole, leur preparation et leur utilisation | |
BE880607A (fr) | Derives de pyrazolo (1,5-c) quinazoline, leur preparation et leur utilisation | |
BE889599A (fr) | Pyridinyl-amino-phenols, leur preparation et leur utilisation comme agents cardiotoniques | |
BE891017A (fr) | Derives de (pyridinyl)benzene, leur preparation et leur utilisation comme agents cardiotoniques |